Targeting G-quadruplex motifs interferes with differentiation of adipose-derived mesenchymal stem cells.
Adipocytes
Differentiation
G-quadruplex
Mesenchymal stem cells
Journal
Stem cell research & therapy
ISSN: 1757-6512
Titre abrégé: Stem Cell Res Ther
Pays: England
ID NLM: 101527581
Informations de publication
Date de publication:
19 04 2023
19 04 2023
Historique:
received:
24
11
2022
accepted:
29
03
2023
medline:
21
4
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
epublish
Résumé
G-quadruplex (G4) motifs are nucleic acid secondary structures observed in mammalian genomes and transcriptomes able to regulate various cellular processes. Several small molecules have been developed so far to modulate G4 stability, frequently associated with anticancer activity. However, how G4 structures are regulated over homeostatic conditions is mostly unexplored. Here, we used human adipose-derived mesenchymal stem cells (ASCs) to address the role of G4 motifs during adipogenic differentiation. Adipocyte differentiation of ASCs was investigated in the presence or absence of a well-known G4 ligand, Braco-19. Cell viability was determined by sulforhodamine B assay. Cell dimension and granularity, DNA G4 motifs and cell cycle were detected by flow cytometry. Lipid droplet accumulation was assessed by Oil Red O staining. Cell senescence was evaluated by β-galactosidase staining. Gene expression was measured by qPCR. Protein release in the extracellular medium was quantified by ELISA. Braco-19 used at non-cytotoxic concentrations induced morphological changes in mature adipocytes partially restoring an undifferentiated-like status. Braco-19 reduced lipid vacuolization and PPARG, AP2, LEP and TNFA mRNA levels in terminally differentiated cells. No effect was observed in cell senescence, fibrotic markers, IL-6 and IL-8 production, while the secretion of VEGF was dose-dependently reduced. Interestingly, G4 structures were increased in differentiated adipocytes compared to their precursors. Braco-19 treatment reduced G4 content in mature adipocytes. Our data highlight a new role of G4 motifs as genomic structural elements related to human ASC differentiation into mature adipocytes, with potential implications in physio-pathological processes.
Sections du résumé
BACKGROUND
G-quadruplex (G4) motifs are nucleic acid secondary structures observed in mammalian genomes and transcriptomes able to regulate various cellular processes. Several small molecules have been developed so far to modulate G4 stability, frequently associated with anticancer activity. However, how G4 structures are regulated over homeostatic conditions is mostly unexplored. Here, we used human adipose-derived mesenchymal stem cells (ASCs) to address the role of G4 motifs during adipogenic differentiation.
METHODS
Adipocyte differentiation of ASCs was investigated in the presence or absence of a well-known G4 ligand, Braco-19. Cell viability was determined by sulforhodamine B assay. Cell dimension and granularity, DNA G4 motifs and cell cycle were detected by flow cytometry. Lipid droplet accumulation was assessed by Oil Red O staining. Cell senescence was evaluated by β-galactosidase staining. Gene expression was measured by qPCR. Protein release in the extracellular medium was quantified by ELISA.
RESULTS
Braco-19 used at non-cytotoxic concentrations induced morphological changes in mature adipocytes partially restoring an undifferentiated-like status. Braco-19 reduced lipid vacuolization and PPARG, AP2, LEP and TNFA mRNA levels in terminally differentiated cells. No effect was observed in cell senescence, fibrotic markers, IL-6 and IL-8 production, while the secretion of VEGF was dose-dependently reduced. Interestingly, G4 structures were increased in differentiated adipocytes compared to their precursors. Braco-19 treatment reduced G4 content in mature adipocytes.
CONCLUSIONS
Our data highlight a new role of G4 motifs as genomic structural elements related to human ASC differentiation into mature adipocytes, with potential implications in physio-pathological processes.
Identifiants
pubmed: 37076894
doi: 10.1186/s13287-023-03320-9
pii: 10.1186/s13287-023-03320-9
pmc: PMC10116735
doi:
Substances chimiques
Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Informations de copyright
© 2023. The Author(s).
Références
Front Chem. 2018 Jul 24;6:281
pubmed: 30137743
Cytokine. 2021 Jun;142:155493
pubmed: 33713881
Stem Cells. 2014 Jun;32(6):1578-90
pubmed: 24375761
Viruses. 2021 Dec 08;13(12):
pubmed: 34960727
Nat Rev Endocrinol. 2010 Apr;6(4):195-213
pubmed: 20195269
Chem Biol Drug Des. 2022 Jan;99(1):1-31
pubmed: 34148284
Cells. 2022 Aug 10;11(16):
pubmed: 36010559
Mol Cancer Ther. 2004 Oct;3(10):1201-6
pubmed: 15486186
Br J Pharmacol. 2008 Mar;153(5):1003-10
pubmed: 18157162
Nucleic Acids Res. 2014 Mar;42(5):2945-57
pubmed: 24335081
J Histochem Cytochem. 2014 Feb;62(2):103-8
pubmed: 24309509
Biochem Biophys Res Commun. 2020 Oct 8;531(1):45-50
pubmed: 32312519
Chem Commun (Camb). 2014 Jun 21;50(49):6422-38
pubmed: 24695755
ACS Appl Mater Interfaces. 2017 Oct 25;9(42):36596-36605
pubmed: 28980796
Nat Commun. 2022 Jan 10;13(1):142
pubmed: 35013231
Stem Cells. 2007 May;25(5):1270-8
pubmed: 17255520
Cell Death Dis. 2015 Jan 22;6:e1610
pubmed: 25611385
Stem Cell Res Ther. 2015 Dec 09;6:242
pubmed: 26652025
Stem Cells. 2007 Apr;25(4):818-27
pubmed: 17420225
Acta Biochim Biophys Sin (Shanghai). 2018 Jul 1;50(7):718-722
pubmed: 29796650
Biochem Pharmacol. 2007 Sep 1;74(5):679-89
pubmed: 17631279
Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22504-9
pubmed: 20018750
Stem Cells. 2007 Nov;25(11):2896-902
pubmed: 17901396
Diabetologia. 2012 Oct;55(10):2811-2822
pubmed: 22798065
Cytometry A. 2018 Jan;93(1):32-49
pubmed: 28906582
Stem Cells Dev. 2013 Jan 15;22(2):279-95
pubmed: 22827698
J Med Chem. 2012 Nov 26;55(22):9785-92
pubmed: 23057850
Mol Pharmacol. 2002 May;61(5):1154-62
pubmed: 11961134
Front Oncol. 2019 Jul 12;9:564
pubmed: 31355131
Trends Endocrinol Metab. 2007 Apr;18(3):100-7
pubmed: 17317207
J Hepatol. 2020 Aug;73(2):371-382
pubmed: 32165252
Cancers (Basel). 2019 Nov 15;11(11):
pubmed: 31731707
Chem Biol Drug Des. 2020 Nov;96(5):1292-1304
pubmed: 32516846
Lab Invest. 2017 Oct;97(10):1158-1166
pubmed: 28414326
Mol Cell. 1999 Oct;4(4):597-609
pubmed: 10549291
Nucleic Acids Res. 2013 Feb 1;41(3):2034-46
pubmed: 23268444
Asian Pac J Cancer Prev. 2014;15(23):10115-9
pubmed: 25556435
Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):31-38
pubmed: 30278241
PPAR Res. 2014;2014:537865
pubmed: 24790595
Cancers (Basel). 2022 Nov 03;14(21):
pubmed: 36358839
Oncotarget. 2016 Mar 22;7(12):14925-39
pubmed: 26908447
Front Microbiol. 2020 Jun 26;11:1269
pubmed: 32714288
Nucleic Acids Res. 2013 Dec;41(22):10584-92
pubmed: 24005038